Recce Pharmaceuticals Ltd (R9Q)

Overview

Recce Pharmaceuticals Ltd is a pioneering biotechnology company based in Sydney, Australia, with operational reach in Australia, the United States, and the United Kingdom. Originally established in 2007 as Recce Limited, the company underwent a name change in November 2017 to better reflect its evolving mission in the pharmaceutical landscape. Recce Pharmaceuticals is dedicated to the discovery, development, and commercialization of novel synthetic anti-infectives. This innovative approach aims to combat the rising threat of antibiotic resistance and address critical needs in global health. The company stands out for its commitment to tackling some of the most challenging infectious diseases, including those caused by superbugs, through a robust pipeline of proprietary compounds.

Products and Services

• RECCE 327

  This lead candidate is a synthetic anti-infective designed to combat blood infections and sepsis, primarily caused by E. coli and S. aureus bacteria, including strains that have developed resistance to existing antibiotics. RECCE 327's development focuses on addressing the urgent need for new treatments against these life-threatening conditions.

• RECCE 529

  As part of Recce Pharmaceuticals’ broader anti-infective portfolio, RECCE 529 targets viral infections. This synthetic compound is being explored for its potential to provide a new option to treat various viral diseases, reflecting the company's commitment to innovation in the anti-infective space.

• RECCE 435

  RECCE 435 represents a significant advancement in antibiotic technology, being a synthetic polymer antibiotic formulated for oral use. This development is particularly noteworthy as it aims to offer a more convenient treatment option for patients, potentially improving adherence and outcomes.

• R327 Intravenous

  This form of RECCE 327 is tailored for intravenous delivery, targeting serious or life-threatening bacterial infections, including sepsis. Currently in phase 1 clinical trials, it represents a critical component of the company’s efforts to provide effective treatments for these perilous conditions.

• Urinary Tract Infections, including Urosepsis

  Focusing on the treatment of urinary tract infections and the potentially life-threatening condition of urosepsis, Recce is pioneering the application of its synthetic anti-infective compounds in new areas. The development in this field is aimed at phase 2 clinical trials.

• R327 Topical

  Expanding the application of RECCE 327, this topical formulation is designed to treat wound infections, including those from infected burns and diabetic foot ulcer infections. Currently in phase 2 trials, it highlights Recce's approach to versatile drug development.

• Pre-Clinical Programs

  Recce Pharmaceuticals is also heavily invested in pre-clinical programs that target a range of infections, from Mycobacterium abscessus in phase 1 clinical trials to bacterial sinusitis and additional TBD (to be announced) conditions, showcasing the breadth of the company's research and development efforts.